Nature of Business (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) segment product	Dec. 31, 2021 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of operating segments | segment	1
Modifier gene therapy platform, number of products | product	1
Net loss	$ (81,351)	$ (58,365)
Accumulated deficit	213,018	$ 131,667
Cash and investments	$ 90,900